Interview with Swee-Yeok CHU, CEO & President, EDBI/Bio One Capital
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
Address: 250 North Bridge Road,#28-00 Raffles City Tower, Singapore 179101,Singapore
Tel: +65 6832 6832
Web: http://www.edbi.com/
Bio One Capital is a leading strategic investment firm headquartered in Singapore with a worldwide presence investing to drive growth opportunities within the knowledge and innovation-intensive sectors of Biomedical Sciences, Clean Technologies, Internet & Digital Media, as well as other strategic industry clusters with commercial potential. As a value adding investor, they create sustainable and synergistic partnerships with their portfolio companies, leveraging on their broad network of resources and experience to facilitate the companies’ organic growth in Asia and the world, through their operations in Singapore
Investment firm
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
What is the global R&D vision of Takeda, Japan’s largest pharmaceutical company that recently celebrated its 230th birthday? Takeda’s global R&D vision is committed to the discovery and development of…
Singapore wants to be seen as a springboard for Asia, but that is a position that other countries in Asia would also like to hold. In general, executives prefer to…
Since the last time we had the pleasure of meeting you, 4 years ago, what have been the main developments and changes in the Singaporean pharmaceutical industry? One of the…
What prompted you to found TriReme six years ago? I set up companies, so TriReme was not the first. The idea behind TriReme was to provide solutions for complex cases,…
Central Asia, what is Central Asia in the BD perspective? For us, Central Asia includes all the countries in Asia, except Greater China, India and Japan. What have been the…
The company’s current corporate strategy includes a major focus on the Emerging Markets and Asia Pacific (EMAP) region. Concretely, what are the expectations and the main objectives for the Asia…
Please give us an overview of HOYA Surgical Optics and its operations. HOYA Surgical Optics is a global manufacturer of intraocular lenses (IOLs) — the artificial lens that is put…
There has been much hype about emerging markets, especially those in Asia. How important are these markets for GE and what are your respective goals for the next three years?…
As a pioneering member of Arcasia, before it merged with JTC International and became what is Ascendas today, you know the history of the company very intimately. What are the…
In Q3 2012, MSD reported worldwide sales of $11.5 billion. What was the contribution that emerging markets had? From an MSD perspective, emerging markets refer to every market outside North…
Pfizer completed the acquisition of Wyeth three years ago. How did the merge impact the Singaporean operations? As the result of the merge, Pfizer in Singapore has been able to…
Prior to joining AMRI you worked in diverse companies in Japan, like Dishman, Pfizer and Bayer. What attracted you to this company? The main reason is that Singapore has growing…
See our Cookie Privacy Policy Here
